Capricor Therapeutics Inc. stocks have been trading up by 12.49 percent amid strong optimism over its lead cell therapy pipeline.
Click Here for a Millionaire's POV on Trading CAPR
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- B. Riley upgraded Capricor Therapeutics to Buy from Neutral, boosting its target from $5 to $21 ahead of a key 2026/11/22 FDA action date for deramiocel.
- Piper Sandler raised Capricor Therapeutics to Overweight from Neutral and hiked its price target from $2 to $25, citing an attractive risk/reward setup into the same FDA decision.
- Shares of CAPR popped roughly 4–5% after Piper Sandler’s upgrade and aggressive price target increase, highlighting sensitivity to analyst calls.
- CAPR climbed more than 4% on B. Riley’s upgrade and target jump, reinforcing the link between bullish research and short-term price spikes.
- A new Schedule 13G filing disclosed a sizable passive stake in Capricor Therapeutics, adding another layer of confidence from larger capital.
Live Update At 12:32:36 EDT: On Wednesday, September 30, 2026 Capricor Therapeutics Inc. stock [NASDAQ: CAPR] is trending up by 12.49%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Capricor Therapeutics, trading under ticker CAPR, has been acting like a classic event-driven biotech. Over the past couple of weeks, the daily chart shows CAPR grinding higher from the mid‑$8s to around $9.64, with multiple tests of the $9–$10 area. That tells traders there is steady dip-buying ahead of the 2026/11/22 FDA action date for deramiocel.
Intraday, CAPR’s 5‑minute chart shows big volatility early, with a spike above $11 before fading back toward $10 and then the high‑$9s. That kind of fast move and pullback is textbook momentum behavior — great for day traders who manage risk, dangerous for anyone who chases.
More Breaking News
- Accenture Stock Extends Rally As AI Deals And New Units Fuel Growth Story
- FRMI Stock Slides As Weak Financials Test Trader Patience
- Accenture Stock Jumps As AI Deals And New Units Fuel Momentum
- CYPH Stock Pulls Back As Traders Gauge Next Move
On the fundamentals, CAPR is still a development‑stage biotech. The latest quarterly report shows a net loss of about $40.7M and negative operating cash flow near $31.5M. Returns on equity and assets are deep in the red, and revenue trends are weak. But the balance sheet is not broken: roughly $237.9M in cash and short‑term investments and a current ratio of 7.4 give Capricor Therapeutics a solid liquidity cushion. For traders, CAPR is all about the catalyst path, not current profits.
Why Traders Are Watching CAPR Into November
CAPR is on the radar for momentum traders because the story has a clear clock. Both B. Riley and Piper Sandler are pointing at the same catalyst: the 2026/11/22 FDA action date for deramiocel. When multiple firms line up ahead of a binary event and sharply raise targets, short‑term traders pay attention.
B. Riley’s move from Neutral to Buy with a price target jump from $5 to $21 is not a small tweak. It signals the firm sees a much better risk/reward profile as the FDA decision approaches, and it also highlights possible additional data from an open‑label extension that may show up at the World Muscle Society conference on 2026/10/03. That gives CAPR two clear near‑term dates where headlines can move the stock.
Piper Sandler added fuel earlier in the month, lifting Capricor Therapeutics from Neutral to Overweight and hiking its target from $2 to $25. The market reaction was quick: CAPR popped about 4–5% on that call alone. The same pattern repeated after the B. Riley upgrade, with shares gaining more than 4%. This tells traders CAPR is highly responsive to sentiment shifts and research coverage.
Layer on top the Street’s broader Overweight stance and an average price target reportedly around $31.78, and CAPR suddenly looks like a consensus bullish bet in the small‑cap biotech lane. The fresh Schedule 13G showing a significant passive stake adds another confirmation that larger capital pools are positioning. For active traders, this cocktail — catalysts, upgrades, and institutional‑style interest — sets the stage for elevated volatility into November.
Conclusion
Capricor Therapeutics is a classic biotech catalyst setup. CAPR is losing money today, burning cash on research and trials, and its profitability metrics are ugly. But the company holds a large cash pile, carries manageable leverage, and trades with a chart that reflects growing speculation around deramiocel’s 2026/11/22 FDA decision and potential data at the 2026/10/03 conference.
Two major upgrades — Piper Sandler to Overweight with a $25 target and B. Riley to Buy with a $21 target — have already sparked successive 4–5% pops in CAPR. The wider Street leaning Overweight with an average target near $31.78 shows the bullish view is not isolated. Add the newly disclosed passive stake via a Schedule 13G, and the message is clear: more eyes are on CAPR now than a few weeks ago.
For traders, the key is discipline. CAPR’s intraday swings from the $11s back below $10 show how fast momentum can flip. As Tim Sykes often says, “Volatile stocks are the best teachers — they reward discipline and punish laziness.” As Tim Bohen, lead trainer with StocksToTrade says, “Time and experience have taught me that missed opportunities are part of the game. There’s always another setup around the corner.” CAPR fits that mold. Study the chart, respect your risk, and remember this is educational and research content, not a signal to buy or sell.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.